Jennifer Stumph

Pathologist, Mom, Calvinist

[Tony Breu @tony_breu]

1/14
Why can't you use direct oral anticoagulants (DOACs) in patients with mechanical valves (MVs)?

DOACs have been one of the most important advances in my career. And yet, the presence of a MV is one of the few contraindications.

The reason highlights the unique nature of thrombus formation in those with a MV and provides insights into the evolution of human hemostasis.

[Charlie Herndon @DrCycloPath]

#TooFarToDiagnose? 🧐
Panniculitis.
A. Erythema induratum
B. Polyarteritis Nodosa
C. Erythema nodosum
D. Lupus panniculitis
#Pathology #Dermatology #Dermatopathology #DermPath

[Vincent Rajkumar @VincentRK]

Just out in the New England Journal of Medicine!

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM https://t.co/7dza0YrFh5

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!

How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here!

MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review

@myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR

[Andrew Bellizzi 🇺🇦 @IHC_guy]

I'm thrilled to announce our next @ISIMMweb webinar scheduled for Wednesday, Jan 14 at 11 am ET.

My IHC Big Brother, Jeff Goldsmith, is presenting "Analytic Validation of Clinical Immunohistochemistry Assays: Past, Present, and Future."

Register here: https://t.co/JXM476Suxd

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Another of #hemepath 🩸 🔬marathon in the books, on the new #Leukemia service. Here’s a select handful of interesting cases I saw today… 🧵
1. Acute erythroid leukemia, TP53 mutated.
Note the elongated “carrot – like” nucleoli, often membrane-bound (arrow) on H&E, the large blast with raw nuclei and deeply basophilic cytoplasm with vacuoles on the smear, and the P 53 IHC showing strong nuclear over expression (mutant pattern). By flow, the blast were CD117 +, CD123 - and CD36 bright + with partial CD 34 expression.

[Aneeza Irfan @aneezairfan01]

Join us for our LYMPHOMA UNKNOWN CONFERENCE on 10/03/2025 with Jahg Wong, MD / L. JEFFREY MEDEIROS, MD at 4:00 CST

Zoom: https://t.co/iLeGitIIMn
Passcode: 644987

Slides: https://t.co/jJklTobdru

Case histories:

[ILLIASUL IBAD @IlliasulK]

Every time I heard Erdheim–Chester or Rosai–Dorfman I was 🤯 confused.
“What is this? Definitely not my cup of tea!”

But once you know the key difference 👇

•Erdheim–Chester → CD68+, CD1a–, Touton giant cells

•Langerhans → CD68+, CD1a+, S100+

•Rosai–Dorfman → CD68+, CD1a–, S100+, emperipolesis

Trust me—suddenly it all makes sense. 🧩

#Rheumatology #Immunology
#Sullysrounds #MedX #Medtwitter #Mnemonics #Medicine #History
@DrAkhilX @IhabFathiSulima @Janetbirdope @Lupusreference @RheumNow #MedTwitter #RheumTwitter
@drkeithsiau

[Abhijit Das, MD @AbhijitSurgPath]

Diffuse gliomas - basic facts for residents

#whocnstumors
#makesurgipatheasy

[Raza Hoda, MD @RazaHoda]

Case of Adenoid Cystic Carcinoma 🍪🔬

Dual-cell tumor with epithelial + myoepithelial cells forming cribriform nests 🧇.

Basement membrane material 🍬 made by abluminal myoepithelial cells fills spaces.

🪄 p63 highlights the biphasic pattern.

#PathX #PathTwitter #breastpath

[aung phyo @pathphyo]

Female, 34 week pregnancy with cervical growth. Clinically suspected Ca cervix. Colposcopy and biopsy done.
A case of cervical decidual nodule.

[Alnoor, MD النور اکبر @alnoorakber]

Publication alert!

Pleased to share our new article on Idiopathic Multicentric Castleman Disease.

Thank you everyone who contributed to this publication, and special gratitude to Bob Ohgami for your mentorship 😊

https://t.co/qP7wPfl5ve

[Aneeza Irfan @aneezairfan01]

You are invited to our LYMPHOMA UNKNOWN CONFERENCE on 9/12/2025 with Mahreen Hussain, MD / L. JEFFREY MEDEIROS, MD at 4pm CST

Zoom link: https://t.co/BVkf02XYNP

Passcode:974209

Slides: https://t.co/z3RPzuHDrA

Case histories

[Aneeza Irfan @aneezairfan01]

Please join us for our LYMPHOMA UNKNOWN CONFERENCE on 9/05/2025 with Jahg Wong, MD / L. JEFFREY MEDEIROS, MD at 4pm CST

Zoom link: https://t.co/lSnCIzbhUP
Passcode: 790825

Slides: https://t.co/OBOHR2FZzT

Case histories:

[Jerad Gardner, MD @JMGardnerMD]

Inflammatory #dermpath 101 video: https://t.co/iehlmO5xG7. Spongiotic, vacuolar interface, lichenoid, psoriasiform...a practical algorithmic approach to rashes for #dermatology / #pathology trainees & general #pathologists. #pathTwitter #dermatologia #dermtwitter

[cherians @sindhucherian]

Did you know… Not all CD38 directed targeted therapy has the same impact on flow cytometry studies. To learn more, see this recent report in the @BrJHaem brought to you by @AfshinShameli .

https://t.co/ZDY80MrTGT

[Modern Pathology @ModernPathology]

H3K27me3 loss is good but not perfect for confirming a diagnosis of malignant peripheral nerve sheath tumor; this one arose in a diffuse neurofibroma.
1: Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016 Jan;29(1):4-13. PMID: 26585554.
2: Le Guellec S, Macagno N, Velasco V, Lamant L, Lae M, Filleron T, Malissen N, Cassagnau E, Terrier P, Chevreau C, Ranchere-Vince D, Coindre JM. Loss of H3K27
trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017 Dec;30(12):1677-1687. PMID: 28752843.

[Alireza Mansouri @DrAMansouri]

Gliomas 101: Gene Changes Explained Simply 🧠: I frequently get asked to clarify what each of the genetic abnormalities are in gliomas. The key ones to remember are IDH, MGMT, TERT promoter mutation, CDKN2A, and EGFR:
1. IDH acts like a brake, slowing growth vs. wildtype's speed
2. MGMT methylation: Silences a repair gene, making chemo (temozolomide) more effective. Predictive superpower—methylated? Better shot at response!
3. Other markers on the radar: CDKN2A deletion (worse outlook), TERT promoter (immortal cells), EGFR variants (growth boosters). Future targets!
4. These results? Game-changers for trials—IDH+ might open targeted options. Precision over guesswork!
@WeTrialshub @theABTA

[American Journal of Dermatopathology @AJDP_Journal]

#WhatsNewInDermpath
Histiocytoid sweet syndrome as a manifestation of myelodysplasia cutis/cutaneous VEXAS Syndrome

73YM with myelodysplastic syndrome presented with an acute eruption of erythematous violaceous & indurated dermal nodules and plaques

Figure 3: (A) CD163, (B) MPO

[PaulYoungMD @PaulYoungMD1]

You are invited to join our MDACC Bone Marrow Unknown Conference with Dr Lianqun Qiu on Wednesday, June 18th at 9:15am CST.

Slides are here: https://t.co/DrmcLIgnnb

Zoom link: https://t.co/WJtdauWC8p

[PaulYoungMD @PaulYoungMD1]

You are invited to join our MDACC Lymphoma Unknown Conference with Dr Wei Wang on Friday, June 6th at 4:00pm CST. Four cases, plus lots of flow cytometry.

Slides are here: https://t.co/E3dx7kRpxE

Zoom link: https://t.co/Hcymjw70Lb